Related Experiment Video
Updated: Aug 3, 2025

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
Nirmatrelvir-ritonivir, COVID-19, and possible adverse cutaneous reactions
J Mark Albrecht, Benjamin R Cooper, Jacquelyn D Waller
1Department of Epidemiology, Colorado School of Public Health, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA Dermatology Service, U.S. Department of Veterans Affairs Rocky Mountain Regional Medical Center, Aurora, Colorado, USA. Robert.dellavalle@ucdenver.edu.
Abstract:
Nirmatrelvir-ritonivir (Paxlovid) recently received emergency use authorization for the treatment of coronavirus disease 2019 (COVID-19). Literature has linked numerous cutaneous adverse effects to nirmatrelvir and ritonavir, the copackaged tablets within Paxlovid. A review and comparison of these adverse effects to the common cutaneous manifestations of COVID-19 is provided. Numerous drug-to-drug interactions exist between nirmatrelvir-ritonivir and commonly-used medications within dermatology.
Related Concept Videos
Myocarditis III: Medical Management
Subviral Agents
Allergic Drug Reactions
Retroviruses
Transmission-based Precautions I: Contact, Enteric, and Droplets
Contact Precautions:
Contact precautions are the measures taken to prevent the transmission of infectious agents, especially epidemiologically important microorganisms such as MRSA or influenza, primarily transmitted through direct or indirect contact with an...
Antimicrobial Effectiveness

